522 related articles for article (PubMed ID: 31421115)
21. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
[TBL] [Abstract][Full Text] [Related]
22. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
23. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
24. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
Fujita K; Iguchi Y; Une M; Watanabe S
Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
[TBL] [Abstract][Full Text] [Related]
25. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
26. Protective effects of gomisin N against hepatic steatosis through AMPK activation.
Yun YR; Kim JH; Kim JH; Jung MH
Biochem Biophys Res Commun; 2017 Jan; 482(4):1095-1101. PubMed ID: 27914812
[TBL] [Abstract][Full Text] [Related]
27. Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats.
Tan Y; Kim J; Cheng J; Ong M; Lao WG; Jin XL; Lin YG; Xiao L; Zhu XQ; Qu XQ
World J Gastroenterol; 2017 Jun; 23(21):3805-3814. PubMed ID: 28638220
[TBL] [Abstract][Full Text] [Related]
28. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
29. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway.
Chen S; Sun S; Feng Y; Li X; Yin G; Liang P; Yu W; Meng D; Zhang X; Liu H; Zhang F
Eur J Pharmacol; 2023 Aug; 952():175808. PubMed ID: 37263401
[TBL] [Abstract][Full Text] [Related]
30. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
31. Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction.
Jin SH; Yang JH; Shin BY; Seo K; Shin SM; Cho IJ; Ki SH
Toxicol Appl Pharmacol; 2013 Aug; 271(1):95-105. PubMed ID: 23651738
[TBL] [Abstract][Full Text] [Related]
32. Leonurus japonicus Houtt Attenuates Nonalcoholic Fatty Liver Disease in Free Fatty Acid-Induced HepG2 Cells and Mice Fed a High-Fat Diet.
Lee MR; Park KI; Ma JY
Nutrients; 2017 Dec; 10(1):. PubMed ID: 29295591
[TBL] [Abstract][Full Text] [Related]
33. (5R)-5-hydroxytriptolide ameliorates liver lipid accumulation by suppressing lipid synthesis and promoting lipid oxidation in mice.
Dong Y; Lu H; Li Q; Qi X; Li Y; Zhang Z; Chen J; Ren J
Life Sci; 2019 Sep; 232():116644. PubMed ID: 31301418
[TBL] [Abstract][Full Text] [Related]
34. Coniferaldehyde ameliorates the lipid and glucose metabolism in palmitic acid-induced HepG2 cells via the LKB1/AMPK signaling pathway.
Gai H; Zhou F; Zhang Y; Ai J; Zhan J; You Y; Huang W
J Food Sci; 2020 Nov; 85(11):4050-4060. PubMed ID: 33037652
[TBL] [Abstract][Full Text] [Related]
35. Dietary α-lactalbumin induced fatty liver by enhancing nuclear liver X receptor αβ/sterol regulatory element-binding protein-1c/PPARγ expression and minimising PPARα/carnitine palmitoyltransferase-1 expression and AMP-activated protein kinase α phosphorylation associated with atherogenic dyslipidaemia, insulin resistance and oxidative stress in Balb/c mice.
López-Oliva ME; Garcimartin A; Muñoz-Martínez E
Br J Nutr; 2017 Dec; 118(11):914-929. PubMed ID: 29173234
[TBL] [Abstract][Full Text] [Related]
36. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.
Li X; Wang Z; Klaunig JE
Toxicology; 2019 Mar; 416():1-14. PubMed ID: 30711707
[TBL] [Abstract][Full Text] [Related]
37. Food-drug interaction: Anabolic steroids aggravate hepatic lipotoxicity and nonalcoholic fatty liver disease induced by trans fatty acids.
Santos JDB; Mendonça AAS; Sousa RC; Silva TGS; Bigonha SM; Santos EC; Gonçalves RV; Novaes RD
Food Chem Toxicol; 2018 Jun; 116(Pt B):360-368. PubMed ID: 29704577
[TBL] [Abstract][Full Text] [Related]
38. Acanthoic acid suppresses lipin1/2 via TLR4 and IRAK4 signalling pathways in EtOH- and lipopolysaccharide-induced hepatic lipogenesis.
Song J; Han X; Yao YL; Li YM; Zhang J; Shao DY; Hou LS; Fan Y; Song SZ; Lian LH; Nan JX; Wu YL
J Pharm Pharmacol; 2018 Mar; 70(3):393-403. PubMed ID: 29341132
[TBL] [Abstract][Full Text] [Related]
39. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
[TBL] [Abstract][Full Text] [Related]
40. Consumption of soy protein isolate reduces hepatic SREBP-1c and lipogenic gene expression in wild-type mice, but not in FXR-deficient mice.
Hashidume T; Sasaki T; Inoue J; Sato R
Biosci Biotechnol Biochem; 2011; 75(9):1702-7. PubMed ID: 21897047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
